DPXE-7 is under clinical development by IMV and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DPXE-7’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DPXE-7 is under development for the treatment of HPV associated cervical, oropharyngeal, anal, and head and neck cancers. The drug candidate is formulated as a powder to be reconstituted as oil-based formulation and administered through parenteral route. It is developed based on Depovax technology platform. It acts by targeting human papillomavirus protein E7.
IMV is a biopharmaceutical company that develops immunotherapies and vaccines to treat cancer and infectious diseases. The company is investigating its pipeline candidates DPX-Survivac against ovarian, bladder, liver and DPX-RSV for Respiratory Syncytial Virus (RSV) and DPX-Covid-19 for treating coronavirus. It is also advancing DPX-SurMAGE against bladder cancer. IMV harnesses its proprietary DPX platform technology to deliver drugs. The company partners with pharmaceutical companies, academic research institutions and government agencies to research and develop cancer therapies. IMV is headquartered in Dartmouth, Nova Scotia, Canada.
For a complete picture of DPXE-7’s drug-specific PTSR and LoA scores, buy the report here.